- Home
- IPSC vs BRNS Comparison
IPSC vs BRNS Comparison
Compare IPSC & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- BRNS
- Stock Information
- Founded
- IPSC 2019
- BRNS 2016
- Country
- IPSC United States
- BRNS United Kingdom
- Employees
- IPSC N/A
- BRNS N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- BRNS Health Care
- Exchange
- IPSC Nasdaq
- BRNS Nasdaq
- Market Cap
- IPSC 42.2M
- BRNS 48.3M
- IPO Year
- IPSC 2021
- BRNS 2021
- Fundamental
- Price
- IPSC $0.49
- BRNS $1.12
- Analyst Decision
- IPSC Strong Buy
- BRNS Strong Buy
- Analyst Count
- IPSC 5
- BRNS 1
- Target Price
- IPSC $3.33
- BRNS $3.00
- AVG Volume (30 Days)
- IPSC 698.6K
- BRNS 29.9K
- Earning Date
- IPSC 08-14-2025
- BRNS 08-07-2025
- Dividend Yield
- IPSC N/A
- BRNS N/A
- EPS Growth
- IPSC N/A
- BRNS N/A
- EPS
- IPSC N/A
- BRNS N/A
- Revenue
- IPSC $114,128,000.00
- BRNS $14,969,000.00
- Revenue This Year
- IPSC $1,589.94
- BRNS N/A
- Revenue Next Year
- IPSC N/A
- BRNS N/A
- P/E Ratio
- IPSC N/A
- BRNS N/A
- Revenue Growth
- IPSC 5491.77
- BRNS 1766.46
- 52 Week Low
- IPSC $0.34
- BRNS $0.64
- 52 Week High
- IPSC $1.86
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- IPSC 37.35
- BRNS 42.86
- Support Level
- IPSC $0.46
- BRNS $1.10
- Resistance Level
- IPSC $0.55
- BRNS $1.33
- Average True Range (ATR)
- IPSC 0.04
- BRNS 0.12
- MACD
- IPSC -0.00
- BRNS -0.01
- Stochastic Oscillator
- IPSC 25.00
- BRNS 18.35
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.